MDT

83.55

-5.41%↓

VEEV

213.88

-3.96%↓

A

104.72

-5.07%↓

HQY

78.27

-6.52%↓

PDCO

31.06

-0.58%↓

MDT

83.55

-5.41%↓

VEEV

213.88

-3.96%↓

A

104.72

-5.07%↓

HQY

78.27

-6.52%↓

PDCO

31.06

-0.58%↓

MDT

83.55

-5.41%↓

VEEV

213.88

-3.96%↓

A

104.72

-5.07%↓

HQY

78.27

-6.52%↓

PDCO

31.06

-0.58%↓

MDT

83.55

-5.41%↓

VEEV

213.88

-3.96%↓

A

104.72

-5.07%↓

HQY

78.27

-6.52%↓

PDCO

31.06

-0.58%↓

MDT

83.55

-5.41%↓

VEEV

213.88

-3.96%↓

A

104.72

-5.07%↓

HQY

78.27

-6.52%↓

PDCO

31.06

-0.58%↓

Search

OPKO Health Inc

Abrir

SetorSaúde

1.56 -2.5

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.54

Máximo

1.59

Indicadores-chave

By Trading Economics

Rendimento

-11M

14M

Vendas

10M

184M

EPS

0.01

Margem de lucro

7.638

Funcionários

2,997

EBITDA

-17M

73M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+63.06% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-2.7B

1.1B

Abertura anterior

4.06

Fecho anterior

1.56

Sentimento de Notícias

By Acuity

19%

81%

36 / 386 Ranking em Healthcare

OPKO Health Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de mar. de 2025, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. -- Barrons.com

Comparação entre Pares

Variação de preço

OPKO Health Inc Previsão

Preço-alvo

By TipRanks

63.06% parte superior

Previsão para 12 meses

Média 2.56 USD  63.06%

Máximo 3 USD

Mínimo 2 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para OPKO Health Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

4

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

36 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre OPKO Health Inc

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.